Anti-PKD1L2 monoclonal antibody

Pre-made anti-PKD1L2 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to PKD1L2/PKD1L2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1403-Ab-1/ GM-Tg-hg-IP1403-Ab-2Anti-Human PKD1L2 monoclonal antibodyHuman
GM-Tg-rg-IP1403-Ab-1/ GM-Tg-rg-IP1403-Ab-2Anti-Rat PKD1L2 monoclonal antibodyRat
GM-Tg-mg-IP1403-Ab-1/ GM-Tg-mg-IP1403-Ab-2Anti-Mouse PKD1L2 monoclonal antibodyMouse
GM-Tg-cynog-IP1403-Ab-1/ GM-Tg-cynog-IP1403-Ab-2Anti-Cynomolgus/ Rhesus macaque PKD1L2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1403-Ab-1/ GM-Tg-felg-IP1403-Ab-2Anti-Feline PKD1L2 monoclonal antibodyFeline
GM-Tg-cang-IP1403-Ab-1/ GM-Tg-cang-IP1403-Ab-2Anti-Canine PKD1L2 monoclonal antibodyCanine
GM-Tg-bovg-IP1403-Ab-1/ GM-Tg-bovg-IP1403-Ab-2Anti-Bovine PKD1L2 monoclonal antibodyBovine
GM-Tg-equg-IP1403-Ab-1/ GM-Tg-equg-IP1403-Ab-2Anti-Equine PKD1L2 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1403-Ab-1/ GM-Tg-hg-IP1403-Ab-2; GM-Tg-rg-IP1403-Ab-1/ GM-Tg-rg-IP1403-Ab-2;
GM-Tg-mg-IP1403-Ab-1/ GM-Tg-mg-IP1403-Ab-2; GM-Tg-cynog-IP1403-Ab-1/ GM-Tg-cynog-IP1403-Ab-2;
GM-Tg-felg-IP1403-Ab-1/ GM-Tg-felg-IP1403-Ab-2; GM-Tg-cang-IP1403-Ab-1/ GM-Tg-cang-IP1403-Ab-2;
GM-Tg-bovg-IP1403-Ab-1/ GM-Tg-bovg-IP1403-Ab-2; GM-Tg-equg-IP1403-Ab-1/ GM-Tg-equg-IP1403-Ab-2
Products NameAnti-PKD1L2 monoclonal antibody
Formatmab
Target NamePKD1L2
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-PKD1L2 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1403-Ag-1Recombinant multi-species PK1L2/ PKD1L2/ PC1L2 protein


    Target information

    Target IDGM-IP1403
    Target NamePKD1L2
    Gene ID114780,691069,717465,489696,101084591,101905746,100069843
    Gene Symbol and SynonymsPC1L2,PKD1L2
    Uniprot AccessionQ7Z442
    Uniprot Entry NamePK1L2_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000166473
    Target ClassificationIon Channel

    The target: PKD1L2, gene name: PKD1L2, also named as PC1L2. This gene encodes a member of the polycystin protein family. This protein may function as a G-protein-coupled component or regulator of cation channel pores. The long isoform of this protein contains 11 transmembrane domains, a latrophilin/CL-1-like GPCR proteolytic site (GPS) domain, and a polycystin-1, lipoxygenase, alpha-toxin (PLAT) domain. Alternative splicing results in multiple transcript variants encoding distinct isoforms. This gene is a polymorphic pseudogene in humans. [provided by RefSeq, May 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.